Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis.

Citation data:

Autopsy & case reports, ISSN: 2236-1960, Vol: 8, Issue: 2, Page: e2018011

Publication Year:
2018
Captures 4
Readers 4
PMID:
29780751
DOI:
10.4322/acr.2018.011
Author(s):
Simões, Joana; Augusto, Isabel; Meireles, Sara; Vendeira, Lurdes; Silva, Carlos
Publisher(s):
Editora Cubo Multimidia
article description
At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223.